Literature DB >> 18059369

Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA.

Xuguang Chen1, Dianne M Kube, Mark J Cooper, Pamela B Davis.   

Abstract

Compacted DNA nanoparticles deliver transgenes efficiently to the lung following intrapulmonary dosing. Here we show that nucleolin, a protein known to shuttle between the nucleus, cytoplasm, and cell surface, is a receptor for DNA nanoparticles at the cell surface. By using surface plasmon resonance (SPR), we demonstrate that nucleolin binds to DNA nanoparticles directly. The presence of nucleolin on the surface of HeLa and 16HBEo- cells was confirmed by surface biotinylation assay and immunofluorescence. Rhodamine-labeled DNA nanoparticles colocalize with nucleolin on the cell surface, as well as in the cytoplasm and nucleus, but not with transferrin or markers of early endosome or lysosome following cellular uptake. Reducing nucleolin on the cell surface by serum-free medium or siRNA against nucleolin treatment leads to significant reduction in luciferase reporter gene activity, while overexpressing nucleolin has the opposite effect. Competition for binding to DNA nanoparticles with exogenous purified nucleolin decreases the transfection efficiency by 60-90% in a dose-dependent manner. Therefore, the data strongly suggest that cell surface nucleolin serves as a receptor for DNA nanoparticles, and that nucleolin is essential for internalization and/or transport of the nanoparticles from cell surface to the nucleus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059369     DOI: 10.1038/sj.mt.6300365

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  52 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Non-degradative intracellular trafficking of highly compacted polymeric DNA nanoparticles.

Authors:  Anthony J Kim; Nicholas J Boylan; Jung Soo Suk; Samuel K Lai; Justin Hanes
Journal:  J Control Release       Date:  2011-10-30       Impact factor: 9.776

3.  Reducible DNA nanoparticles enhance in vitro gene transfer via an extracellular mechanism.

Authors:  Wenchao Sun; Pamela B Davis
Journal:  J Control Release       Date:  2010-05-12       Impact factor: 9.776

4.  Optimization of hCFTR lung expression in mice using DNA nanoparticles.

Authors:  Linas Padegimas; Tomasz H Kowalczyk; Sam Adams; Chris R Gedeon; Sharon M Oette; Karla Dines; Susannah L Hyatt; Ozge Sesenoglu-Laird; Olena Tyr; Robert C Moen; Mark J Cooper
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 5.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

6.  Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example.

Authors:  Quinn K T Ng; Marie K Sutton; Pan Soonsawad; Li Xing; Holland Cheng; Tatiana Segura
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

Review 7.  AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

Authors:  Zongchao Han; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-10       Impact factor: 4.799

Review 8.  Nanotechnology: toxicologic pathology.

Authors:  Ann F Hubbs; Linda M Sargent; Dale W Porter; Tina M Sager; Bean T Chen; David G Frazer; Vincent Castranova; Krishnan Sriram; Timothy R Nurkiewicz; Steven H Reynolds; Lori A Battelli; Diane Schwegler-Berry; Walter McKinney; Kara L Fluharty; Robert R Mercer
Journal:  Toxicol Pathol       Date:  2013-02-06       Impact factor: 1.902

9.  Non-covalent ligand conjugation to biotinylated DNA nanoparticles using TAT peptide genetically fused to monovalent streptavidin.

Authors:  Wenchao Sun; David Fletcher; Rolf Christiaan van Heeckeren; Pamela B Davis
Journal:  J Drug Target       Date:  2012-09       Impact factor: 5.121

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.